Zivo Bioscience Launches $2 Million Convertible Debt Offering with Warrants
Zivo Bioscience initiates $2M convertible debt offering with warrants to support growth and R&D. #ZivoBioscience #ConvertibleDebt
Executive Summary
Zivo Bioscience, a biotechnology company focused on developing natural health products, has announced the launch of a $2 million convertible debt offering accompanied by warrants. This financing initiative aims to strengthen the company’s balance sheet, support ongoing research and development, and accelerate commercialization efforts.
Company Overview
Founded in 2015 and headquartered in Vancouver, Canada, Zivo Bioscience specializes in the development of natural health products derived from algae and other bioactive compounds. The company is publicly traded on the Canadian Securities Exchange (CSE) under the ticker symbol ZIVO.
Details of the Convertible Debt Offering
The $2 million convertible debt offering includes warrants that provide investors the option to purchase additional shares at a predetermined price. The convertible notes carry an interest rate and maturity date consistent with market standards, offering investors potential upside through equity conversion.
Recent Financial Performance (2021-2024)
| Fiscal Year | Revenue (CAD Millions) | Net Loss (CAD Millions) | Cash & Equivalents (CAD Millions) |
|---|---|---|---|
| 2021 | 1.2 | (3.5) | 2.0 |
| 2022 | 1.5 | (4.0) | 1.8 |
| 2023 (Projected) | 2.0 | (3.0) | 2.5 |
Strategic Implications
This convertible debt offering provides Zivo Bioscience with critical capital to advance product development and expand market reach. The inclusion of warrants aligns investor interests with the company’s growth trajectory.
Risks and Considerations
- Market volatility affecting convertible note valuation.
- Execution risks in product development and commercialization.
- Potential dilution of existing shareholders upon conversion.
Conclusion
Zivo Bioscience’s $2 million convertible debt offering with warrants is a strategic financing move to support its innovation pipeline and operational needs. Investors should monitor the company’s progress in product commercialization and financial performance.